Patents by Inventor Steven R. Ledbetter

Steven R. Ledbetter has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antibodies to TGF-Beta
    Publication number: 20230078449
    Abstract: The present invention relates to antibody molecules, in particular antibody molecules that bind Transforming Growth Factor beta (TGF?) and uses thereof. More particularly, the invention relates to antibody molecules that bind and preferably neutralise TGF?1, TGF?2 and TGF?3, so-called “pan-specific” antibody molecules, and uses of such antibody molecules. Preferred embodiments within the present invention are antibody molecules, whether whole antibody (e.g. IgG, such as IgG1 or IgG4) or antibody fragments (e.g. scFv, Fab, dAb).
    Type: Application
    Filed: September 16, 2022
    Publication date: March 16, 2023
    Applicants: Genzyme Corporation, Optein, Inc.
    Inventors: Steven R. Ledbetter, Celia Patricia Hart, Robert G. Holgate, Lutz U. Jermutus, Catriona L. Buchanan, Alexander R. Duncan, Donna K. Finch
  • Antibodies to TGF-Beta
    Publication number: 20210061897
    Abstract: The present invention relates to antibody molecules, in particular antibody molecules that bind Transforming Growth Factor beta (TGF?) and uses thereof. More particularly, the invention relates to antibody molecules that bind and preferably neutralise TGF?1, TGF?2 and TGF?3, so-called “pan-specific” antibody molecules, and uses of such antibody molecules. Preferred embodiments within the present invention are antibody molecules, whether whole antibody (e.g. IgG, such as IgG1 or IgG4) or antibody fragments (e.g. scFv, Fab, dAb).
    Type: Application
    Filed: August 19, 2020
    Publication date: March 4, 2021
    Applicants: Genzyme Corporation, Optein, Inc.
    Inventors: Steven R. Ledbetter, Celia Patricia Hart, Robert G. Holgate, Lutz U. Jermutus, Catriona L. Buchanan, Alexander R. Duncan, Donna K. Finch
  • Antibodies to TGF-?
    Patent number: 10781252
    Abstract: The present invention relates to antibody molecules, in particular antibody molecules that bind Transforming Growth Factor beta (TGF?), and uses thereof. More particularly, the invention relates to antibody molecules that bind and preferably neutralise TGF?1, TGF?2 and TGF?3, so-called “pan-specific” antibody molecules, and uses of such antibody molecules. Preferred embodiments within the present invention are antibody molecules, whether whole antibody (e.g. IgG, such as IgG1 or IgG4) or antibody fragments (e.g. scFv, Fab, dAb).
    Type: Grant
    Filed: November 21, 2018
    Date of Patent: September 22, 2020
    Assignees: Genzyme Corporation, Optein, Inc.
    Inventors: Steven R. Ledbetter, Celia Patricia Hart, Robert G. Holgate, Lutz U. Jermutus, Catriona L. Buchanan, Alexander R. Duncan, Donna K. Finch
  • Antibodies to TGF-Beta
    Publication number: 20190177406
    Abstract: The present invention relates to antibody molecules, in particular antibody molecules that bind Transforming Growth Factor beta (TGF?), and uses thereof. More particularly, the invention relates to antibody molecules that bind and preferably neutralise TGF?1, TGF?2 and TGF?3, so-called “pan-specific” antibody molecules, and uses of such antibody molecules. Preferred embodiments within the present invention are antibody molecules, whether whole antibody (e.g. IgG, such as IgG1 or IgG4) or antibody fragments (e.g. scFv, Fab, dAb).
    Type: Application
    Filed: November 21, 2018
    Publication date: June 13, 2019
    Applicants: Genzyme Corporation, Optein, Inc.
    Inventors: Steven R. Ledbetter, Celia Patricia Hart, Robert G. Holgate, Lutz U. Jermutus, Catriona L. Buchanan, Alexander R. Duncan, Donna K. Finch
  • METHOD OF TREATING PRIMARY FOCAL SEGMENTAL GLOMERULOSCLEROSIS
    Publication number: 20190062416
    Abstract: A method of treating primary focal segmental glomerulosclerosis in a patient having an APOL1 variant, comprising intravenously administering a TGF? antagonist to the patient.
    Type: Application
    Filed: June 17, 2016
    Publication date: February 28, 2019
    Applicant: GENZYME CORPORATION
    Inventors: Steven R. Ledbetter, Sara Engstrand, Patrick Finn, Julie Lin, Robert John Pomponio
  • Antibodies to TGF-beta
    Patent number: 10174108
    Abstract: The present invention relates to antibody molecules, in particular antibody molecules that bind. Transforming Growth Factor beta (TGF?), and uses thereof. More particularly, the invention relates to antibody molecules that bind and preferably neutralize TGF?1, TGF?2 and TGF?3, so-called “pan-specific” antibody molecules, and uses of such antibody molecules. Preferred embodiments within the present invention are antibody molecules, whether whole antibody (e.g. IgG, such as IgG1 or IgG4) or antibody fragments (e.g. scFv, Fab, dAb).
    Type: Grant
    Filed: September 28, 2016
    Date of Patent: January 8, 2019
    Assignees: Genzyme Corporation, Optein, Inc.
    Inventors: Steven R. Ledbetter, Celia Patricia Hart, Robert G. Holgate, Lutz U. Jermutus, Catriona L. Buchanan, Alexander R. Duncan, Donna K. Finch
  • ANTIBODIES TO TGF-BETA
    Publication number: 20170066821
    Abstract: The present invention relates to antibody molecules, in particular antibody molecules that bind. Transforming Growth Factor beta (TGF?), and uses thereof. More particularly, the invention relates to antibody molecules that bind and preferably neutralise TGF?1, TGF?2 and TGF?3, so-called “pan-specific” antibody molecules, and uses of such antibody molecules. Preferred embodiments within the present invention are antibody molecules, whether whole antibody (e.g. IgG, such as IgG1 or IgG4) or antibody fragments (e.g. scFv, Fab, dAb).
    Type: Application
    Filed: September 28, 2016
    Publication date: March 9, 2017
    Applicants: Genzyme Corporation, Optein, Inc.
    Inventors: Steven R. Ledbetter, Celia Patricia Hart, Robert G. Holgate, Lutz U. Jermutus, Catriona L. Buchanan, Alexander R. Duncan, Donna K. Finch
  • Antibodies to TGF-?
    Patent number: 9481726
    Abstract: The present invention relates to antibody molecules, in particular antibody molecules that bind Transforming Growth Factor beta (TGF?), and uses thereof. More particularly, the invention relates to antibody molecules that bind and preferably neutralize TGF?1, TGF?2 and TGF?3, so-called “pan-specific” antibody molecules, and uses of such antibody molecules. Preferred embodiments within the present invention are antibody molecules, whether whole antibody (e.g. IgG, such as IgG1 or IgG4) or antibody fragments (e.g. scFv, Fab, dAb).
    Type: Grant
    Filed: April 9, 2015
    Date of Patent: November 1, 2016
    Assignee: GENZYME CORPORATION
    Inventors: Steven R. Ledbetter, Celia Patricia Hart, Robert G. Holgate, Lutz U. Jermutus, Catriona L. Buchanan, Alexander R. Duncan, Donna K. Finch
  • ANTIBODIES TO TGF-BETA
    Publication number: 20150284456
    Abstract: The present invention relates to antibody molecules, in particular antibody molecules that bind Transforming Growth Factor beta (TGF?), and uses thereof. More particularly, the invention relates to antibody molecules that bind and preferably neutralise TGF?1, TGF?2 and TGF?3, so-called “pan-specific” antibody molecules, and uses of such antibody molecules. Preferred embodiments within the present invention are antibody molecules, whether whole antibody (e.g. IgG, such as IgG1 or IgG4) or antibody fragments (e.g. scFv, Fab, dAb).
    Type: Application
    Filed: April 9, 2015
    Publication date: October 8, 2015
    Inventors: Steven R. Ledbetter, Celia Patricia Hart, Robert G. Holgate, Lutz U. Jermutus, Catriona L. Buchanan, Alexander R. Duncan, Donna K. Finch
  • Antibodies to TGF-beta
    Patent number: 9090685
    Abstract: The present invention relates to antibody molecules, in particular antibody molecules that bind Transforming Growth Factor beta (TGF?), and uses thereof. More particularly, the invention relates to antibody molecules that bind and preferably neutralize TGF?1, TGF?2 and TGF?3, so-called “pan-specific” antibody molecules, and uses of such antibody molecules. Preferred embodiments within the present invention are antibody molecules, whether whole antibody (e.g. IgG, such as IgG1 or IgG4) or antibody fragments (e.g. scFv, Fab, dAb).
    Type: Grant
    Filed: October 21, 2013
    Date of Patent: July 28, 2015
    Assignees: Genzyme Corporation, Optein, Inc.
    Inventors: Steven R. Ledbetter, Celia Patricia Hart, Robert G. Holgate, Lutz U. Jermutus, Catriona L. Buchanan, Alexander R. Duncan, Donna K. Finch
  • ANTIBODIES TO TGF-BETA
    Publication number: 20140127230
    Abstract: The present invention relates to antibody molecules, in particular antibody molecules that bind Transforming Growth Factor beta (TGF?), and uses thereof. More particularly, the invention relates to antibody molecules that bind and preferably neutralise TGF?1, TGF?2 and TGF?3, so-called “pan-specific” antibody molecules, and uses of such antibody molecules. Preferred embodiments within the present invention are antibody molecules, whether whole antibody (e.g. IgG, such as IgG1 or IgG4) or antibody fragments (e.g. scFv, Fab, dAb).
    Type: Application
    Filed: October 21, 2013
    Publication date: May 8, 2014
    Inventors: Steven R. Ledbetter, Celia Patricia Hart, Robert G. Holgate, Lutz U. Jermutus, Catriona L. Buchanan, Alexander R. Duncan, Donna K. Finch
  • Antibodies to TGF-?
    Patent number: 8591901
    Abstract: The present invention relates to antibody molecules, in particular antibody molecules that bind Transforming Growth Factor beta (TGF?), and uses thereof. More particularly, the invention relates to antibody molecules that bind and preferably neutralize TGF?1, TGF?2 and TGF?3, so-called “pan-specific” antibody molecules, and uses of such antibody molecules. Preferred embodiments within the present invention are antibody molecules, whether whole antibody (e.g. IgG, such as IgG1 or IgG4) or antibody fragments (e.g. scFv, Fab, dAb).
    Type: Grant
    Filed: September 13, 2012
    Date of Patent: November 26, 2013
    Assignees: Genzyme Corporation, Optein, Inc
    Inventors: Steven R Ledbetter, Celia P Hart, Robert G Holgate, Lutz U Jermutus, Catriona L Buchanan, Alexander R Duncan, Donna K Finch
  • ANTIBODIES TO TGF-BETA
    Publication number: 20130243788
    Abstract: The present invention relates to antibody molecules, in particular antibody molecules that bind. Transforming Growth Factor beta (TGF?), and uses thereof. More particularly, the invention relates to antibody molecules that bind and preferably neutralise TG?1, TGF?2 and TGF?3, so-called “pan-specific” antibody molecules, and uses of such antibody molecules. Preferred embodiments within the present invention are antibody molecules, whether whole antibody (e.g. IgG, such as IgG1 or IgG4) or antibody fragments (e.g. scFv, Fab, dAb).
    Type: Application
    Filed: September 13, 2012
    Publication date: September 19, 2013
    Applicant: GENZYME CORPORATION
    Inventors: Steven R. Ledbetter, Celia P. Hart, Robert G. Holgate, Lutz U. Jermutus, Catriona L. Buchanan, Alexander R. Duncan, Donna K. Finch
  • Antibodies to TGF?
    Patent number: 8383780
    Abstract: The present invention relates to antibody molecules, in particular antibody molecules that bind Transforming Growth Factor beta (TGF?), and uses thereof. More particularly, the invention relates to antibody molecules that bind and preferably neutralize TGF?1, TGF?2 and TGF?3, so-called “pan-specific” antibody molecules, and uses of such antibody molecules. Preferred embodiments within the present invention are antibody molecules, whether whole antibody (e.g. IgG, such as IgG1 or IgG4) or antibody fragments (e.g. scFv, Fab, dAb).
    Type: Grant
    Filed: March 15, 2010
    Date of Patent: February 26, 2013
    Assignees: Genzyme Corporation, Optein, Inc.
    Inventors: Steven R. Ledbetter, Celia P. Hart, Robert G. Holgate, Lutz U. Jermutus, Catriona L. Buchanan, Alexander R. Duncan, Donna K. Finch
  • ANTIBODIES TO TGF-BETA
    Publication number: 20110008364
    Abstract: The present invention relates to antibody molecules, in particular antibody molecules that bind Transforming Growth Factor beta (TGF?), and uses thereof. More particularly, the invention relates to antibody molecules that bind and preferably neutralise TGF?1, TGF?2 and TGF?3, so-called “pan-specific” antibody molecules, and uses of such antibody molecules. Preferred embodiments within the present invention are antibody molecules, whether whole antibody (e.g. IgG, such as IgG1 or IgG4) or antibody fragments (e.g. scFv, Fab, dAb).
    Type: Application
    Filed: March 15, 2010
    Publication date: January 13, 2011
    Applicant: GENZYME CORPORATION
    Inventors: Steven R. Ledbetter, Celia P. Hart, Robert G. Holgate, Lutz U. Jermutus, Catriona L. Buchanan, Alexander R. Duncan, Donna K. Finch
  • FUSION PROTEINS CONTAINING TWO TGF-BETA BINDING DOMAINS OF TGF-BETA TYPE II RECEPTOR
    Publication number: 20100204104
    Abstract: The disclosure provides fusion proteins that contain two TGF-? binding domains of TGF-? type II receptor joined to each other by a linker. For example, the C terminus of the first TGF-? binding domain is joined by a short peptide linker (e.g., a 9-glycine linker) to the N terminus of the second TGF-? binding domain. Despite the proximity of the C terminus of the first domain to N terminus of the second domain, such a fusion protein effectively neutralizes TGF-?, in some cases, similarly to anti-TGF-? antibodies.
    Type: Application
    Filed: December 24, 2008
    Publication date: August 12, 2010
    Inventors: Huawei Qiu, Steven R. Ledbetter, Sirkka Kyostio-Moore
  • Antibodies to TGF-?
    Patent number: 7723486
    Abstract: The present invention relates to antibody molecules, in particular antibody molecules that bind Transforming Growth Factor beta (TGF?), and uses thereof. More particularly, the invention relates to antibody molecules that bind and preferably neutralize TGF?1, TGF?2 and TGF?3, so-called “pan-specific” antibody molecules, and uses of such antibody molecules. Preferred embodiments within the present invention are antibody molecules, whether whole antibody (e.g. IgG, such as IgG1 or IgG4) or antibody fragments (e.g. scFv, Fab, dAb).
    Type: Grant
    Filed: February 8, 2006
    Date of Patent: May 25, 2010
    Assignees: Optein, Inc., Genzyme Corporation
    Inventors: Steven R. Ledbetter, Celia P. Hart, Robert G. Holgate, Lutz U. Jermutus, Catriona L. Buchanan, Alexander R. Duncan, Donna K. Finch
  • Use of minoxidil for wound healing
    Patent number: 4912111
    Abstract: A method for the promotion or acceleration of wound healing by a treatment with minoxidil is disclosed. The minoxidial can be administered by topical application, oral administration, injection or any combination thereof. Treatment with minoxidil is effective for promoting the migration of epithelial cells in a wound or in tissues such as cornea and the like. Methods for identifying binding sites for minoxidil in cells based on their affinity for the compound in attachment or chemotactic assays are described.
    Type: Grant
    Filed: December 7, 1988
    Date of Patent: March 27, 1990
    Assignees: The Upjohn Company, NIDR NIH
    Inventors: Anthony C. Sank, George R. Martin, Steven R. Ledbetter